Absci to participate in the virtual conference HC Wainwright BIOCONNECT | Nation / world
VANCOUVER, Wash., Dec. 30, 2021 (GLOBE NEWSWIRE) – Absci Corporation (Nasdaq: ABSI), the drug and target discovery company that leverages deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced today announced that the company announced its participation in the HC Wainwright BIOCONNECT virtual conference.
Absci management is expected to give a presentation on Monday, January 10th at 4:00 AM Pacific Time / 7:00 AM Eastern Time. Interested parties can access a live and archived webcast of the presentation in the “Investors” area of the company website at www.absci.com.
About Absci
Absci is the drug and target discovery company that uses deep learning and synthetic biology to expand the therapeutic potential of proteins. We designed our Integrated Drug Creation ™ platform to identify new drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture in a single efficient process. Biotech and pharmaceutical innovators are working with us to create the next generation of protein-based drugs, including those that other technologies may not be able to make. Our goal is to enable the development of better drugs through Translating Ideas into Drugs ™. For more information, visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci.
Availability of more information on Absci
Investors and others should note that we routinely communicate with investors and the public through our website (www.absci.com) and the “Investors” section of our website (investors.absci.com), particularly through the publication of investor presentations, SEC – Submissions, press releases, public conference calls and webcasts on these websites. The information that we publish on these websites can be considered material information. Therefore, investors, the media and others interested in Absci are encouraged to review this information regularly. The content of our website or any other website accessible from our website is not deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended.
Investor contact
Media contact
Copyright 2021 GlobeNewswire, Inc.